Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation

Fig. 4

Evaluation of the effects of gemcitabine on the transcriptional activation of the uPAR promoter. a Analysis of E1A gene expression in BxPC-3 and PANC-1 cells infected with AduPARE1A and treated with gemcitabine (20 ng/ml and 250 μg/ml) for 24 h. b Analysis of E1A gene expression in BxPC-3 cells infected with increasing viral doses in the presence or absence of 10 ng/ml of gemcitabine. c Analysis of TK gene expression in BxPC-3, PANC-1 and MIAPaCa-2 cell lines transduced with AduPARTKT (18.790 vp/cell, 1466 vp/cell and 11716 vp/cell, respectively) and treated with gemcitabine (20 ng/ml, 250 μg/ml and 20 ng/ml respectively) for 24 h. d Luciferase activity in BxPC-3, PANC-1 and MIAPaCa-2 cell lines transduced with 10 MOI (BxPC-3, PANC-1) or 20 MOI (MIAPaCa-2) of AduPARLUC and treated or not with gemcitabine (20 ng/ml, 250 μg/ml and 20 ng/ml respectively) for 24 h. Results are expressed as RLU (LU/μg of protein). e Expression of endogenous uPAR gene in BxPC-3, PANC-1 and MIAPaCa-2 cell lines treated with gemcitabine (20 ng/ml, 250 μg/ml and 20 ng/ml respectively) for 24 h. Results are represented as the mean ± SEM of at least three independent experiments

Back to article page

Molecular Cancer

ISSN: 1476-4598